Paper41127013
Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability.
Li R and 7 others. Front Oncol, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability. Papers, record 41127013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41127013
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33926917 | A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33926917 | PubMed |
| 2 | 33264544 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/33264544 | PubMed |
| 3 | 35506567 | NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. | Cancer Med | 2022 | https://conductscience.org/library/papers/35506567 | PubMed |
| 4 | 35977594 | Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas. | Hum Pathol | 2022 | https://conductscience.org/library/papers/35977594 | PubMed |
| 5 | 22933939 | Microsatellite instability in colorectal cancer. | Radiol Oncol | 2011 | https://conductscience.org/library/papers/22933939 | PubMed |
| 6 | 35680043 | Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35680043 | PubMed |
| 7 | 37142372 | Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/37142372 | PubMed |
| 8 | 30925919 | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. | Mol Cancer | 2019 | https://conductscience.org/library/papers/30925919 | PubMed |
| 9 | 35131862 | Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35131862 | PubMed |
| 10 | 39874977 | Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. | Lancet | 2025 | https://conductscience.org/library/papers/39874977 | PubMed |
| 11 | 32343640 | Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32343640 | PubMed |
| 12 | 39035212 | Cancer incidence and mortality in China, 2016. | J Natl Cancer Cent | 2022 | https://conductscience.org/library/papers/39035212 | PubMed |
| 13 | 30742119 | Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. | Nat Med | 2019 | https://conductscience.org/library/papers/30742119 | PubMed |
| 14 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 15 | 37894457 | Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37894457 | PubMed |
| 16 | 39629124 | BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/β-catenin pathway. | Theranostics | 2024 | https://conductscience.org/library/papers/39629124 | PubMed |
| 17 | 36700211 | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/36700211 | PubMed |
| 18 | 35896284 | Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35896284 | PubMed |
| 19 | 29891791 | TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29891791 | PubMed |
| 20 | 31611702 | Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. | Nat Immunol | 2019 | https://conductscience.org/library/papers/31611702 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42164656 | Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42164656 | PubMed |
| 41601689 | Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. | Front Immunol | 2025 | https://conductscience.org/library/papers/41601689 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41127013
GET https://conductscience.org/api/papers/v1/41127013/references?page=2